Stopping GLP-1 Drugs May Quickly Reverse Cardiovascular Benefits, Study Suggests
A study by Washington University in St. Louis researchers found that stopping GLP-1 drugs may quickly erase cardiovascular benefits, potentially increasing the risk of heart attack, stroke, and death by up to 22% within two years for individuals with Type…
Tucson, AZ, September 24, 2026 —
Researchers from Washington University in St. Louis have identified a significant risk associated with discontinuing GLP-1 medications, indicating that the cardiovascular benefits these drugs provide may be rapidly lost.
According to the study, stopping GLP-1 drugs could potentially increase the risk of major adverse cardiovascular events, including heart attack, stroke, and death, by as much as 22% within a two-year period for individuals diagnosed with Type 2 diabetes.
The research analyzed data from a large cohort of over 333,000 U.S. veterans. The findings suggest that consistent, ongoing treatment with GLP-1 medications is vital for maintaining these protective cardiovascular effects.
Furthermore, the study indicates that even if patients restart their GLP-1 medication after a period of discontinuation, the protection offered may only be partially restored. This points to the importance of uninterrupted therapy for patients managing Type 2 diabetes who are also at risk for cardiovascular complications.
Story summarized from the original created by Kelly Broderick on www.kgun9.com, see more information here.
